Donald Trump announced a new agreement with AstraZeneca to lower U.S. prescription drug prices by matching the lowest prices offered in other developed countries under a “most-favored-nation” policy.
The deal will apply to Medicaid programs nationwide and could benefit around 9 million patients using AstraZeneca medications for asthma, COPD, heart disease, and cancer. The administration says the agreement could save taxpayers hundreds of millions of dollars each year.
AstraZeneca also pledged to invest $50 billion in U.S. manufacturing and research by 2030, including a new production facility in Charlottesville, Virginia, expected to create 3,600 jobs. Some respiratory drugs are expected to see major price cuts, including large discounts on BEVESPI AEROSPHERE and AIRSUPRA inhalers.
The announcement follows a similar agreement with Pfizer and is part of Trump’s broader effort to reduce prescription drug costs and expand domestic pharmaceutical production.
